Role of Fibrocytes in the Bronchial Remodelling of Chronic Obstructive Pulmonary Disease

Overview

Airway remodelling is an abnormal tissue repair following bronchial inflammation, which contributes to none reversible pathological features, such as bronchial and peri-bronchial fibrosis. It also influences the prognosis of Chronic Obstructive Pulmonary Disease (COPD) and its mechanisms remain largely unknown. The role of fibrocytes has been demonstrated in the pathophysiology of asthma, lung fibrosis or pulmonary hypertension. However, the recruitment of blood fibrocytes and their involvement in COPD airway remodelling remain unknown.

The main objective of the study is to analyse the distribution and quantify the number of the peri-bronchial and blood circulating fibrocytes in patients with different stages of COPD compared to control subjects.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: April 2015

Arms, Groups and Cohorts

  • COPD
    • 15 patients with COPD from 1 to 4 according to the GOLD 2011
  • Non smoker Control
    • 15 patients without COPD and no smoking history
  • Smoker Control
    • 15 patients without COPD but a smoking history

Clinical Trial Outcome Measures

Primary Measures

  • Increased number of peri-bronchial and blood circulating fibrocytes gradually in each stages of COPD and compared to control subjects.
    • Time Frame: Lung tissues and blood samples will be collected at inclusion visit during surgery (Day 0)

Secondary Measures

  • Characterization of fibrocytes: expression of chemokines receptors, Toll Like Receptors, HLA class II
    • Time Frame: Lung tissues and blood samples will be collected at inclusion visit during surgery (Day 0)
  • Correlation between lung attenuation and the number of fibrocytes
    • Time Frame: Assessed one year after inclusion visit (i.e. surgery date =Day 0)
  • Correlation between plethysmography and the number of fibrocytes.
    • Time Frame: Assessed one year after inclusion visit (i.e. surgery date = Day 0)

Participating in This Clinical Trial

Inclusion Criteria

  • Male or female aged more than 40 yr
  • Patient needed a thoracic surgery such as lobectomy for cancer or lung transplantation or lung reduction volume surgery.
  • COPD group: diagnostic of COPD and differentiation of the stage from 1 to 4 according to the GOLD guidelines.
  • Control group: subjects with normal lung function testing and no chronic symptoms (cough or expectoration). Subjects will be separated in 2 groups according to smoking history (Never smokers, smokers (former or current) and paired to patients according to age and sex.
  • with a written informed consent

Exclusion Criteria

  • Subject without any social security or health insurance
  • Asthma, lung fibrosis or idiopathic pulmonary hypertension
  • Chronic viral infections (hepatitis, HIV)
  • Pregnant woman or breastfeeding
  • Subject included for cancer surgery with a Pn0 diagnosis not confirmed after the intervention.

Gender Eligibility: All

Minimum Age: 40 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University Hospital, Bordeaux
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Nicholas MOORE, MD-PhD, Study Chair, University Hospital, Bordeaux
  • Overall Contact(s)
    • Matthieu THUMEREL, MD, (0)557656009, matthieu.thumerel@chu-bordeaux.fr

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.